232 related articles for article (PubMed ID: 27312508)
1. Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa.
Jin L; Boyd BJ; Larson IC; Pennington MW; Norton RS; Nicolazzo JA
J Pharm Sci; 2016 Jul; 105(7):2173-9. PubMed ID: 27312508
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases.
Jin L; Zhou QT; Chan HK; Larson IC; Pennington MW; Morales RAV; Boyd BJ; Norton RS; Nicolazzo JA
J Pharm Sci; 2016 Feb; 105(2):650-656. PubMed ID: 26869426
[TBL] [Abstract][Full Text] [Related]
3. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
4. Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1[R14A], a K
Reddiar SB; Jin L; Wai DCC; Csoti A; Panyi G; Norton RS; Nicolazzo JA
Toxicon; 2021 May; 195():29-36. PubMed ID: 33689790
[TBL] [Abstract][Full Text] [Related]
5. Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats.
Bergmann R; Kubeil M; Zarschler K; Chhabra S; Tajhya RB; Beeton C; Pennington MW; Bachmann M; Norton RS; Stephan H
Sci Rep; 2017 Jun; 7(1):3756. PubMed ID: 28623364
[TBL] [Abstract][Full Text] [Related]
6. A Fluorescent Peptide Toxin for Selective Visualization of the Voltage-Gated Potassium Channel K
Wai DCC; Naseem MU; Mocsár G; Babu Reddiar S; Pan Y; Csoti A; Hajdu P; Nowell C; Nicolazzo JA; Panyi G; Norton RS
Bioconjug Chem; 2022 Nov; 33(11):2197-2212. PubMed ID: 36330854
[TBL] [Abstract][Full Text] [Related]
7. Blockade of Microglial Kv1.3 Potassium Channels by the Peptide HsTX1[R14A] Attenuates Lipopolysaccharide-mediated Neuroinflammation.
Nicolazzo JA; Pan Y; Di Stefano I; Choy KHC; Reddiar SB; Low YL; Wai DCC; Norton RS; Jin L
J Pharm Sci; 2022 Mar; 111(3):638-647. PubMed ID: 34767826
[TBL] [Abstract][Full Text] [Related]
8. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.
Rashid MH; Huq R; Tanner MR; Chhabra S; Khoo KK; Estrada R; Dhawan V; Chauhan S; Pennington MW; Beeton C; Kuyucak S; Norton RS
Sci Rep; 2014 Mar; 4():4509. PubMed ID: 24676092
[TBL] [Abstract][Full Text] [Related]
9. Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases.
Jin L; Boyd BJ; White PJ; Pennington MW; Norton RS; Nicolazzo JA
J Control Release; 2015 Feb; 199():37-44. PubMed ID: 25482338
[TBL] [Abstract][Full Text] [Related]
10. Prolonged Plasma Exposure of the Kv1.3-Inhibitory Peptide HsTX1[R14A] by Subcutaneous Administration of a Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere Formulation.
Jin L; Pan Y; Pham AC; Boyd BJ; Norton RS; Nicolazzo JA
J Pharm Sci; 2021 Mar; 110(3):1182-1188. PubMed ID: 33065128
[TBL] [Abstract][Full Text] [Related]
11. A Biodistribution Study of the Radiolabeled Kv1.3-Blocking Peptide DOTA-HsTX1[R14A] Demonstrates Brain Uptake in a Mouse Model of Neuroinflammation.
Reddiar SB; de Veer M; Paterson BM; Sepehrizadeh T; Wai DCC; Csoti A; Panyi G; Nicolazzo JA; Norton RS
Mol Pharm; 2023 Jan; 20(1):255-266. PubMed ID: 36331024
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Administration of the Kv1.3-Blocking Peptide HsTX1[R14A] Improves Cognitive Performance in Senescence Accelerated SAMP8 Mice.
Pan Y; Kagawa Y; Sun J; Lucas DSD; Takechi R; Mamo JCL; Wai DCC; Norton RS; Jin L; Nicolazzo JA
Neurotherapeutics; 2023 Jul; 20(4):1198-1214. PubMed ID: 37226029
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of various buccal permeation enhancing systems for PACAP (pituitary adenylate cyclase-activating polypeptide).
Langoth N; Bernkop-Schnürch A; Kurka P
Pharm Res; 2005 Dec; 22(12):2045-50. PubMed ID: 16132338
[TBL] [Abstract][Full Text] [Related]
14. Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3/Kv1.1 selectivity.
Rashid MH; Kuyucak S
J Phys Chem B; 2014 Jan; 118(3):707-16. PubMed ID: 24397610
[TBL] [Abstract][Full Text] [Related]
15. The buccal mucosa as an alternative route for the systemic delivery of risperidone.
Heemstra LB; Finnin BC; Nicolazzo JA
J Pharm Sci; 2010 Nov; 99(11):4584-92. PubMed ID: 20845457
[TBL] [Abstract][Full Text] [Related]
16. Buccal delivery of methimazole as an alternative means for improvement of drug bioavailability: permeation studies and matrix system design.
De Caro V; Giandalia G; Siragusa MG; Giannola LI
Curr Pharm Des; 2012; 18(34):5405-10. PubMed ID: 22632389
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional consequences of the presence of a fourth disulfide bridge in the scorpion short toxins: solution structure of the potassium channel inhibitor HsTX1.
Savarin P; Romi-Lebrun R; Zinn-Justin S; Lebrun B; Nakajima T; Gilquin B; Menez A
Protein Sci; 1999 Dec; 8(12):2672-85. PubMed ID: 10631983
[TBL] [Abstract][Full Text] [Related]
18. Azone® decreases the buccal mucosal permeation of diazepam in a concentration-dependent manner via a reservoir effect.
Meng-Lund E; Jacobsen J; Jin L; Janfelt C; Holm R; Müllertz A; Nicolazzo JA
J Pharm Sci; 2014 Apr; 103(4):1133-41. PubMed ID: 24532052
[TBL] [Abstract][Full Text] [Related]
19. Development of a mucoadhesive and permeation enhancing buccal delivery system for PACAP (pituitary adenylate cyclase-activating polypeptide).
Langoth N; Kalbe J; Bernkop-Schnürch A
Int J Pharm; 2005 May; 296(1-2):103-11. PubMed ID: 15885461
[TBL] [Abstract][Full Text] [Related]
20. The Kv1.3 K
Varga Z; Tajti G; Panyi G
Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
